ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat
CBP74003
| I. Background | |
|
抗體依賴的細胞介導的細胞毒性作用（ADCC，antibody-dependent cell-mediated cytotoxicity ）是指抗體的 Fab 段結合病毒感染的細胞或腫瘤細胞的抗原表位，其 Fc 段與殺 傷細胞（NK 細胞、巨噬細胞等）表面的 FcR 結合，介導殺傷細胞直接殺傷靶細胞，它是 抗腫瘤的治療性抗體藥物發(fā)生作用的一種作用重要機制。 傳統(tǒng)用于測定 ADCC/ADCP 的方法主要依賴于相關原代免疫細胞的分離、體外分化， 進而測量靶細胞的殺傷或吞噬效應。這些方法高度依賴供體原代細胞，價格昂貴且費時費 力，對原代細胞的分離分化過程對實驗操作的要求非常高，實驗失敗風險較大，由于分離 分化細胞純度問題，還存在檢測信號低以及不穩(wěn)定均一的問題。另外，原代細胞具有不可 再生性，每次實驗的細胞供體來源可能都不一致，實驗結果可重復性較差，可能存在批次 差異。由于以上這些因素的影響，在需要高質量控制的藥物開發(fā)過程中，很難建立穩(wěn)定可 靠的檢測方法。 |
|
| II. Description | |
|
ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT Jurkat 報告基因藥靶模 型很好的模擬了體內 ADCC 的信號轉導過程，原理見下圖所示。
|
|
| III. Introduction | |
| Host Cell: | Jurkat |
| Expressed gene: | NFAT-Luc-CD16(V158) |
| Stability: | 32 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Synonym(s): | Antibody-dependent cell-mediated cytotoxicity |
| Freeze Medium: | 90% FBS+10% DMSO |
| Culture Medium: | RPMI-1640+10%FBS+300μg/ml hygromycin+1μg/ml puromycin |
| Mycoplasma Testing: | Negative |
| Storage: | Immediately upon receipt, store in liquid nitrogen. |
| Application(s): | Functional(Report Gene) Assay |
| IV. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | Peripheral blood |
| Disease: | Acute T cell leukemia |
| Morphology: | Lymphoblast |
| Growth Properties: | Suspension |
| Ⅴ. Representative Data | |
Figure 2. Recombinant ADCC Bioassay Effector Cell V variant (High Affinity)-Fcγ-NFAT/Jurkat stably expressing CD16a（V158）.
Figure 3. Dose response of CD20 Ab in ADCC Bioassay Effector Cell (High Affinity)-Fcγ-NFAT Jurkat cell（C36）. Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell（C36）with Membrane Anchored TNFα Cells(Suspended,C5).
Figure 4. Dose response of TNFα Abs in ADCC Bioassay Effector Cell V variant(High Affinity)-Fcγ-NFAT Jurkat cell（C36）with Membrane Anchored TNFα Cell (Adherent,C12).
